XenoPort, Inc. (XNPT.O)
18.92USD
9 Feb 2010
$-0.20 (-1.05%)
$18.92
--
$19.36
$18.81
201,690
293,202
$27.83
$13.36
XNPT.O
About
Overall
| Beta: | 0.74 |
| Market Cap (Mil.): | $574.04 |
| Shares Outstanding (Mil.): | 30.34 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| XNPT.O | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 11.50 | 3.76 |
| EPS (TTM): | -46.49 | -- | -- |
| ROI: | -48.67 | 1.25 | 2.30 |
| ROE: | -56.69 | 2.09 | 2.82 |
XenoPort says FDA extends review of restless leg syndrome drug
Nov 9 (Reuters) - XenoPort Inc has said the U.S. health regulators delayed by three months the review of its drug for restless leg syndrome, sending its shares down 4 percent.
UPDATE 3-Depomed's pain drug meets main goal, shares soar
* Depomed shares up 41 pct (Updates share movement; adds CEO comments, details)
UPDATE 1-XenoPort says pain drug meets main goal of trial
* Neuropathic pain drug meets main goal of mid-stage trial
UPDATE 1-XenoPort, Arena shares fall on discounted stock offer
July 8 (Reuters) - Shares of U.S. drugmakers XenoPort Inc and Arena Pharmaceuticals Inc fell more than 11 percent on Wednesday, after their public offering of shares was priced below their Tuesday close.
HEADLINE STOCKS-Some U.S. stocks on the move on July 8
(Updates to after the open, adds Cisco, AT&T, Goldman/Morgan Stanley and Tractor Supply)
HEADLINE STOCKS-Some U.S. stocks to watch on July 8
NEW YORK, July 8 (Reuters) - Some U.S. stocks to watch on Wednesday:
UPDATE 1-XenoPort posts narrower-than-expected Q1 loss
May 5 (Reuters) - Biopharmaceutical company XenoPort Inc posted a narrower-than-expected quarterly loss, helped by higher milestone revenue from one of its products.
UPDATE 2-XenoPort's diabetic pain drug fails in mid-stage trial
* Says diabetic pain drug XP13512 fails to meet main goal
US-RESEARCH/ (NON-S&P500)
Eastern Insurance Fox-Pitt Starts with in line rating Holdings --------------------------------------------------------------- ------------ Euroseas Wachovia Cuts to market perform from
US RESEARCH SUMMARY-Non-S&P 500 March 20 2048 GMT
Following is a summary of research actions on non-S&P 500 companies reported
Competitors
| Price | Change | |
|---|---|---|
| Eli Lilly & Co. (LLY.N) | $35.20 | +0.42 |
| Pfizer Inc. (PFE.N) | $17.88 | +0.04 |
| GlaxoSmithKline plc (GSK.L) | £1,201.50 | -17.00 |
| Johnson & Johnson (JNJ.N) | $62.76 | +0.39 |
| Abbott Laboratories (ABT.N) | $53.35 | 0.00 |
| DepoMed, Inc. (DEPO.OQ) | $2.90 | +0.10 |
| Solvay S.A. (SOLB.BR) | €69.71 | +0.06 |
| Acorda Therapeutics Inc. (ACOR.OQ) | $29.99 | +0.07 |
| AstraZeneca plc (AZN.L) | £2,803.00 | -12.50 |
| Takeda Pharmaceutical Company Limited (4502.T) | ¥3,890.00 | -5.00 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
